Christopher Bowd, None;
Siamak Yousefi, None;
Daniel Meira-Freitas, None;
Michael Goldbaum, None;
Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), Nidek Inc. (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F);
Robert Weinreb, Aerie (F), Alcon Laboratories Inc. (C), Allergan Inc. (C), Bausch & Lomb Inc. (C), Carl Zeiss Meditec Inc. (C), Carl Zeiss Meditec Inc. (F), Genentech (F), Heidelberg Engineering GmbH (F), National Eye Institute (F), Novartis (F), Optovue Inc. (F), Sensimed Inc. (C), Topcon Inc. (C), Topcon Inc. (F);
Jeffrey Liebmann, Allergan Inc. (C), Allergan Inc. (F), Bausch & Lomb Inc. (C), Bausch & Lomb Inc. (F), Carl Zeiss Meditec Inc. (F), Diopsys Inc. (C), Diopsys Inc. (F), Heidelberg Engineering GmbH (C), Heidelberg Engineering GmbH (F), Merz Pharmaceuticals Inc. (C), Optovue Inc. (F), Quark Pharmaceuticals Inc. (F), Reichert Inc. (F), Sensimed Inc. (F), Topcon Inc. (F), Valeant Pharmaceuticals Inc. (C);
Christopher Girkin, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), SOLX (F);
Felipe Medeiros, Alcon Laboratories Inc. (F), Alcon Laboratories Inc. (R), Allergan Inc. (C), Allergan Inc. (R), Bausch & Lomb Inc. (F), Carl Zeiss Meditec Inc. (C), Carl Zeiss Meditec Inc. (F), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering GmbH (F), Merck Inc. (F), Reichert Inc. (F), Reichert Inc. (S), Sensimed Inc. (F), Topcon Inc. (F)